Bristol Historical Cash Flow
BMY Stock | USD 53.25 0.70 1.33% |
Analysis of Bristol Myers cash flow over time is an excellent tool to project Bristol-Myers Squibb future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Free Cash Flow of 13.3 B or Begin Period Cash Flow of 4.8 B as it is a great indicator of Bristol Myers ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Bristol-Myers Squibb latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Bristol-Myers Squibb is a good buy for the upcoming year.
Bristol |
About Bristol Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Bristol balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Bristol's non-liquid assets can be easily converted into cash.
Bristol Myers Cash Flow Chart
Bristol Cash Flow Statement became part of mandatory reporting in 1987. It is now one of three main statements in accounting used to measure how well a company manages its liquidity and overall cash position. The rate of cash utilization and preservation is now part of the leading indicators of a healthy entity, and the Bristol-Myers Squibb Cash Flow Statement shows how well the company generates cash to payout debt obligations or to cover ongoing operating expenses.
At this time, Bristol Myers' Change In Cash is fairly stable compared to the past year. Free Cash Flow is likely to rise to about 13.3 B in 2024, despite the fact that Sale Purchase Of Stock is likely to grow to (4.9 B). Add Fundamental
Free Cash Flow
The amount of cash a company generates after accounting for cash outflows to support operations and maintain its capital assets.Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Capital Expenditures
Capital Expenditures are funds used by Bristol-Myers Squibb to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Bristol Myers operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Most accounts from Bristol Myers' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Bristol-Myers Squibb current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. At this time, Bristol Myers' Change In Cash is fairly stable compared to the past year. Free Cash Flow is likely to rise to about 13.3 B in 2024, despite the fact that Sale Purchase Of Stock is likely to grow to (4.9 B).
Bristol Myers cash flow statement Correlations
Click cells to compare fundamentals
Bristol Myers Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Bristol Myers cash flow statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Sale Purchase Of Stock | (7.3B) | (1.5B) | (6.3B) | (8.0B) | (5.2B) | (4.9B) | |
Change To Inventory | 463M | 2.7B | 13M | (69M) | (751M) | (713.5M) | |
Change In Cash | 5.9B | 2.2B | (657M) | (5.0B) | 2.2B | 2.3B | |
Free Cash Flow | 7.2B | 13.3B | 15.2B | 11.9B | 12.7B | 13.3B | |
Change In Working Capital | 3.1B | 983M | (1.3B) | (2.2B) | (1.9B) | (1.8B) | |
Begin Period Cash Flow | 6.9B | 12.8B | 15.0B | 14.3B | 9.3B | 4.8B | |
Other Cashflows From Financing Activities | (53M) | 542M | 641M | 7.1B | 483M | 583.3M | |
Depreciation | 1.7B | 10.4B | 10.7B | 10.3B | 9.8B | 10.2B | |
Other Non Cash Items | 279M | 9.9B | 570M | 955M | 744M | 781.2M | |
Dividends Paid | 2.7B | 4.1B | 4.4B | 4.6B | (4.7B) | (4.5B) | |
Capital Expenditures | 836M | 753M | 973M | 1.1B | 1.2B | 837.5M | |
Total Cash From Operating Activities | 8.1B | 14.1B | 16.2B | 13.1B | 13.9B | 14.6B | |
Net Income | 3.5B | (9.0B) | 7.0B | 6.3B | 8.0B | 8.4B | |
Total Cash From Financing Activities | 7.6B | (1.2B) | (16.2B) | (17.0B) | (9.4B) | (8.9B) | |
End Period Cash Flow | 12.8B | 15.0B | 14.3B | 9.3B | 11.5B | 12.1B | |
Stock Based Compensation | 441M | 779M | 583M | 457M | 518M | 262.8M | |
Total Cashflows From Investing Activities | (9.8B) | (10.9B) | (538M) | (1.1B) | (955.8M) | (1.0B) | |
Change To Account Receivables | 1.7B | (3.0B) | (2.1B) | (663M) | (995M) | (945.3M) | |
Other Cashflows From Investing Activities | (8.8B) | (12.2B) | (862M) | (3.0B) | (2.7B) | (2.5B) | |
Change To Liabilities | 1.1B | (2.1B) | 45M | (887M) | (798.3M) | (758.4M) | |
Change To Netincome | (62M) | (197M) | (748M) | (1.1B) | (970.2M) | (921.7M) | |
Investments | (152M) | 2.1B | 1.3B | 3.0B | 264M | 270.6M | |
Change Receivables | 752M | (646M) | (1.1B) | (663M) | (596.7M) | (566.9M) | |
Net Borrowings | 17.7B | 3.9B | (6.2B) | (5.3B) | (6.1B) | (5.8B) | |
Cash And Cash Equivalents Changes | 5.9B | 2.0B | (555M) | (5.0B) | (5.7B) | (5.4B) | |
Cash Flows Other Operating | 572M | 13.0B | 251M | (858M) | (986.7M) | (937.4M) | |
Change To Operating Activities | 702M | 1.1B | 606M | (183M) | (210.5M) | (199.9M) |
Bristol Myers Investors Sentiment
The influence of Bristol Myers' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Bristol. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Bristol Myers' public news can be used to forecast risks associated with an investment in Bristol. The trend in average sentiment can be used to explain how an investor holding Bristol can time the market purely based on public headlines and social activities around Bristol Myers Squibb. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Bristol Myers' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Bristol Myers' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Bristol Myers' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Bristol Myers.
Bristol Myers Implied Volatility | 26.54 |
Bristol Myers' implied volatility exposes the market's sentiment of Bristol Myers Squibb stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Bristol Myers' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Bristol Myers stock will not fluctuate a lot when Bristol Myers' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Bristol Myers in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Bristol Myers' short interest history, or implied volatility extrapolated from Bristol Myers options trading.
Pair Trading with Bristol Myers
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol Myers position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol Myers will appreciate offsetting losses from the drop in the long position's value.Moving together with Bristol Stock
0.69 | MDGL | Madrigal Pharmaceuticals Financial Report 14th of May 2024 | PairCorr |
Moving against Bristol Stock
0.7 | MMSI | Merit Medical Systems Financial Report 24th of April 2024 | PairCorr |
0.6 | MBIO | Mustang Bio Report 3rd of April 2024 | PairCorr |
0.56 | KA | Kineta Inc Report 29th of March 2024 | PairCorr |
0.56 | VBIV | VBI Vaccines Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Bristol Myers could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol Myers when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol Myers - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol Myers Squibb to buy it.
The correlation of Bristol Myers is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol Myers moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol-Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol Myers can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bristol Myers Squibb. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.
Complementary Tools for Bristol Stock analysis
When running Bristol Myers' price analysis, check to measure Bristol Myers' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol Myers is operating at the current time. Most of Bristol Myers' value examination focuses on studying past and present price action to predict the probability of Bristol Myers' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bristol Myers' price. Additionally, you may evaluate how the addition of Bristol Myers to your portfolios can decrease your overall portfolio volatility.
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
AI Investment Finder Use AI to screen and filter profitable investment opportunities | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |
Is Bristol Myers' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bristol Myers. If investors know Bristol will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bristol Myers listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.09) | Dividend Share 2.31 | Earnings Share 3.86 | Revenue Per Share 21.753 | Quarterly Revenue Growth 0.006 |
The market value of Bristol-Myers Squibb is measured differently than its book value, which is the value of Bristol that is recorded on the company's balance sheet. Investors also form their own opinion of Bristol Myers' value that differs from its market value or its book value, called intrinsic value, which is Bristol Myers' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bristol Myers' market value can be influenced by many factors that don't directly affect Bristol Myers' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bristol Myers' value and its price as these two are different measures arrived at by different means. Investors typically determine if Bristol Myers is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol Myers' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.